When Eli Lilly set aside its Alzheimer’s prospect solanezumab, it also put a set of sales jobs on the chopping block.
Amgen’s betting it can raise awareness of multiple myeloma by sharing stories—and to do so, it’s enlisting the pros.
People with diabetes are waiting too long to discuss vision problems with their doctors, according to a new study funded by Bayer.
Celgene’s Revlimid just can’t catch a break in the chronic lymphocytic leukemia market—and one analyst isn’t sure it ever will.
Adapt Pharma, maker of a nasal-spray naloxone product to treat opioid overdose, has hired McCann Health Canada to create its first ad campaign for the new med…
Novo Nordisk is taking the price-increase pledge. Three months after Allergan CEO Brent Saunders surprised pharma with a similar vow, Novo says it will limit…
Eli Lilly won a new indication for SGLT2 contender Jardiance, meaning sales reps can now tout its CV death-reduction claims.
Can Roche's Gazyva edge Rituxan even with biosims looming? At least one analyst thinks it may be the only second-gen blood cancer med with a chance to…
Eli Lilly Oncology is working to help physicians guide patients to services that go beyond the scripts they write.
Eli Lilly’s Taltz DTC advertising seems to be giving the drug a boost in the battle against Novartis' Cosentyx.